NCT06879808

Brief Summary

This study was conducted to examine the effect of color therapy on depression, stress, anxiety and quality of life in hemodialysis patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Apr 2024

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2025

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

March 11, 2025

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 17, 2025

Completed
Last Updated

March 17, 2025

Status Verified

March 1, 2025

Enrollment Period

8 months

First QC Date

March 11, 2025

Last Update Submit

March 11, 2025

Conditions

Keywords

AnxietyColor TherapyDepressionHemodialysisNursingQuality of LifeStress

Outcome Measures

Primary Outcomes (2)

  • Depression Anxiety Stress-21 scale (DASS-21)

    The 21-question DASS scale used in the study was taken by Henry and Crawford. This scale (DASS-21) has 7 questions each to measure the dimensions of depression, stress and anxiety. The scale is a 4-point Likert-type scale, coded as 0 "not applicable to me", 1 "somewhat applicable to me", 2 "generally applicable to me", and 3 "completely applicable to me".

    8 week

  • Short Form-12 (SF-12) Quality of Life Scale

    Ware et al. decided to develop a more practical form of the SF-36 that could be administered in a shorter time and developed the SF-12, which contains the same sub-dimensions as the SF-36 by reducing the number of questions. In addition to the fact that the SF-12 was created in such a way that the same component summary scores can be obtained as the SF-36, the fact that it contains fewer items and therefore has a shorter administration time provides a great advantage. Although it has been demonstrated that the SF-36 scale has sufficient validity and reliability in studies conducted in both patient and normal sample groups in our country, the validity and reliability study of the Turkish form of the SF-12, which was developed as a shorter alternative to the SF-36, was attempted. Similar to SF-36, SF-12 consists of 8 sub-dimensions and 12 items including physical functioning (2 items), physical role (2 items), body pain (1 item), general health (1 item), energy (1 item), social function

    8 week

Study Arms (2)

Color therapy group

EXPERIMENTAL

group doing color therapy

Other: Color therapy

No color therapy group

NO INTERVENTION

group not doing color therapy

Interventions

In the experimental group, color therapy was applied 3 days a week for the first two weeks, while no intervention was performed in the third and fourth weeks. In the fifth and seventh weeks, color therapy was applied for 15 minutes each day, while no intervention was performed in the sixth week.

Color therapy group

Eligibility Criteria

Age18 Weeks+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Be on hemodialysis treatment for at least 6 months,
  • No sleeping pills or sedative medication,
  • No physical or cognitive impairment that prevents them from understanding the education and no diagnosis of a psychiatric illness,
  • The patient or someone living in the same household with the patient is literate,
  • Patients have no vision problems,
  • Patients must be 18 years of age or older.

You may not qualify if:

  • Being on hemodialysis treatment for less than 6 months,
  • Taking sleeping pills or sedative medication,
  • Being diagnosed with a physical illness or cognitive impairment or psychiatric illness that prevents understanding the education provided,
  • Illiteracy of the patient and relatives,
  • Patients have vision problems,
  • Refusing to participate in the research,
  • Under 18 years of age

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fırat University

Elâzığ, Merkez, 23119, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Anxiety DisordersDepression

Interventions

Color Therapy

Condition Hierarchy (Ancestors)

Mental DisordersBehavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

Sensory Art TherapiesComplementary TherapiesTherapeuticsPhototherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Gülcan Bahçecioğlu Turan, Associate Professor

    Firat University

    PRINCIPAL INVESTIGATOR
  • Zülfünaz Özer, Associate Professor

    Istanbul Sebahattin Zaim University

    STUDY DIRECTOR
  • Safiye Yanmış, Assistant Professor

    Erzincan Binali Yildirim Universitesi

    STUDY DIRECTOR
  • Mukadder Mollaoğlu, Professor Doctor

    Cumhuriyet University

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: Randomization; participants were divided into two groups by using simple random numbers table, and then the first group which was drawn by lot method was named as the experimental group.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

March 11, 2025

First Posted

March 17, 2025

Study Start

April 1, 2024

Primary Completion

December 1, 2024

Study Completion

February 1, 2025

Last Updated

March 17, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

After the article is published

Locations